Work

Outcomes of patients with advanced cancer and KRAS mutation in phase I clinical trials.

Year: 2013

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2013.31.15_suppl.e22086

Authors: Apostolia Maria Tsimberidou, Rabih Said, Gerald Steven Falchook, Filip Janku, Aung Naing, Ralph Zinner, George R. Blumenschein, Siqing Fu, David S. Hong, Sarina Anne Piha-Paul, Jennifer J. Wheler, Yang Ye, Kenneth R. Hess, Gary A. Palmer, Robert A. Wolff, Razelle Kurzrock

Institutions: The University of Texas MD Anderson Cancer Center, The University of Texas Health Science Center at Houston, Foundation Medicine (United States), University of California San Diego, Moores Cancer Center

Language: English

Topic: Melanoma and MAPK Pathways

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2595009108

Cites:

Cited by:

Related to: 10